Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK ‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
Cancer Medicine · 2024
DOI: 10.1002/cam4.70405 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Qiran Wei und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu Province, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Piperidines, Cost-Benefit Analysis, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
The ALINE trial demonstrated the superiority of alectinib over platinum‐based chemotherapy in resected Anaplastic Lymphoma Kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC). Considering the high cost of alectinib, this study aimed to evaluate the economic value of alectinib compared to platinum‐based chemotherapy for treating early‐stage ALK‐positive NSCLC from the perspective of the Chinese health care system. Materials and Methods We developed a five‐state Markov model with monthly cycles to estimate the lifetime costs, life‐years (LYs), quality‐adjusted life‐years (QALYs), and incremental cost‐effectiveness ratios (ICERs) in terms of cost per LY gained and per QALY gained. Costs were obtained from database, expert opinions and published literature, and utilities were primarily derived from a multicenter cross‐sectional study based on the Chinese population. Costs and outcomes were discounted at 5% per year. Sensitivity analyses and scenario analyses were conducted to assess uncertainty in model results.
Results
Compared to platinum‐based chemotherapy, alectinib increased total costs by $16,245 and provided gains of 2.02 LYs and 1.84 QALYs over a lifetime horizon. ICERs were $8,052/LY and $8,806/QALY. The ICER in terms of cost per QALY gained was most sensitive to the outcome discount rate. Probabilistic sensitivity analysis indicated a 93% probability of alectinib being cost‐effective at a willing‐to pay (WTP) threshold of $12,367/QALY (1 GDP per capita), rising to 100% at $37,100/QALY (3 GDP per capita).
Conclusion
Alectinib appears to be the preferred cost‐effective option in the adjuvant treatment for Chinese patients with resected early‐stage ALK‐positive NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
- Center for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University, Nanjing, Jiangsu Province, China.
ORCID-Profile: Qiran Wei
Zitieren
APA
Wei, Q., Liang, Y., Mao, J., & Guan, X. (2024). Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK ‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System. Cancer Medicine. https://doi.org/10.1002/cam4.70405
Vancouver
Wei Q, Liang Y, Mao J, Guan X. Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK ‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System. Cancer Medicine. 2024. doi:10.1002/cam4.70405
BibTeX
@article{Wei2024,
author = {Wei, Qiran and Liang, Yifang and Mao, Jiahui and Guan, Xin},
title = {Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK ‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70405}
}
EUVIMED